PD-L1 archive

Lymphocyte Count in Blood as a Biomarker to Identify Liver Cancer Patients Who Will Benefit from TKI+PD1 Therapy

Nov 6, 2024

—

by

In recent years, new treatments including targeted and immunotherapy for liver cancer have become prominent options in modern medicine. With the increasing effectiveness of combination therapies, the importance of identifying patients who can benefit most from these combined treatments is highlighted. The current study focuses on evaluating the role of lymphocyte count in the blood…

Clinical-Radiological Model to Differentiate Between Luminal and Non-Luminal Breast Cancer Using Fat-Suppressed T2 Sequence

Nov 6, 2024

—

by

كاتب ذكاء اصطناعي

in مواضيع متنوعة

Breast cancer is one of the most common types of cancer among women worldwide and poses a significant threat to women’s physical and mental health. The types of breast cancer vary based on hormone receptor status, which directly affects treatment strategies and disease outcomes. In this context, there is an urgent need to develop accurate…

Formonertinib as an Effective Treatment for a Patient with Non-Small Cell Lung Cancer with Rare HER2 Mutations

Nov 6, 2024

—

by

كاتب ذكاء اصطناعي

in مواضيع متنوعة

In recent years, mutations in human epidermal growth factor receptor 2 (HER2) have become a growing topic of research and discussion in the field of non-small cell lung cancer (NSCLC). These mutations present significant therapeutic challenges, as their presence is typically associated with disease progression and poor response to conventional treatments. In this article, we…

!Discover over 1,000 fresh articles every day

Tag: PD-L1

Clinical-Radiological Model to Differentiate Between Luminal and Non-Luminal Breast Cancer Using Fat-Suppressed T2 Sequence

Formonertinib as an Effective Treatment for a Patient with Non-Small Cell Lung Cancer with Rare HER2 Mutations